Last reviewed · How we verify

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/k-group-alpha-inc-a-wholly-owned-subsidiary-of-zentalis-pharmaceuticals-inc. Accessed 2026-05-18.

Related